Update shared on08 Aug 2025
Fair value Increased 30%The significant upward revision in Xeris Biopharma Holdings’ price target reflects rising future P/E expectations despite a decline in net profit margin, resulting in a fair value increase from $6.30 to $7.80.
What's in the News
- Xeris Biopharma Holdings raised full-year 2025 total revenue guidance to $280-$290 million from $260-$275 million.
- The company previously reaffirmed 2025 revenue guidance at $260-$275 million.
Valuation Changes
Summary of Valuation Changes for Xeris Biopharma Holdings
- The Consensus Analyst Price Target has significantly risen from $6.30 to $7.80.
- The Future P/E for Xeris Biopharma Holdings has significantly risen from 23.27x to 30.08x.
- The Net Profit Margin for Xeris Biopharma Holdings has significantly fallen from 16.33% to 14.37%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.